# South Korea Hematopoietic Stem Cell Transplantation Market > South Korea Hematopoietic Stem Cell Transplantation Market Research Report By Transplant Type (Allogeneic, Autologous), By Indication (Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, Other Non-Malignant Disorders) and By Application (Bone Marrow Transplant, Peripheral Blood Stem Cells Transplant, Cord Blood Transplant) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 12.22% - **2024:** $ 98.09 Million - **2025:** $ 110.07 Million - **2035:** $ 348.76 Million - **Key Players:** Novartis (CH), Bristol-Myers Squibb (US), Amgen (US), Gilead Sciences (US), Celgene (US), Takeda (JP), Roche (CH), Merck (DE), AstraZeneca (GB) **Report ID:** MRFR/LS/48277-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** April 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-korea-hematopoietic-stem-cell-transplantation-market-50034 --- ## Market Summary ## **South Korea Hematopoietic Stem Cell Transplantation Market Overview** As per MRFR analysis, the South Korea Hematopoietic Stem Cell Transplantation Market Size was estimated at 87.58 (USD Million) in 2023. The South Korea Hematopoietic Stem Cell Transplantation Market Industry is expected to grow from 98(USD Million) in 2024 to 339 (USD Million) by 2035. The South Korea Hematopoietic Stem Cell Transplantation Market CAGR (growth rate) is expected to be around 11.943% during the forecast period (2025 - 2035) **Key South Korea Hematopoietic Stem Cell Transplantation Market Trends Highlighted** The South Korea Hematopoietic Stem Cell Transplantation Market is witnessing several notable trends that are shaping its landscape. One significant driver is the increasing prevalence of hematological disorders, such as leukemia and lymphoma, which has led healthcare providers to adopt stem cell transplantation as a vital treatment option. The country has established a robust healthcare system with advanced medical technology and research facilities, facilitating the growth of this market. Government initiatives, including financial support for research and development in regenerative medicine, further enhance the potential for growth in hematopoietic stem cell therapy.Opportunities to be explored include the expansion of public and private cord blood banks, which can significantly improve patient access to stem cells for transplantation.  South Korea's commitment to supporting biopharmaceutical companies creates a favorable environment for innovation in the field of hematopoietic stem cell transplantation. Additionally, collaborations between academic institutions and healthcare providers can drive clinical research forward, potentially leading to new therapies and treatment protocols. Recent trends indicate an increasing focus on personalized medicine, where treatments are tailored to individual patients based on genetic and biological markers.This shift is complemented by advancements in gene editing technologies, which hold promise for improving patient outcomes after transplantation.  Moreover, as public awareness around stem cell therapy grows, there is a stronger patient advocacy movement pushing for wider access and better quality of care in this area. Overall, the South Korea Hematopoietic Stem Cell Transplantation Market is poised for growth, driven by a combination of technological advancements, government support, and changing patient needs. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **South Korea Hematopoietic Stem Cell Transplantation Market Drivers** **Rising Incidence of Blood Disorders** The growing prevalence of blood diseases, including leukemia and lymphoma, is a major factor propelling the South Korean hematopoietic stem cell transplantation market. With more than 6,000 new cases reported annually in recent years, the Ministry of Health and Welfare in South Korea reports that the number of leukemia patients has been rising significantly. Hematopoietic stem cell transplantation is one of the sophisticated therapeutic options required due to the rise in blood diseases.  The South Korea Hematopoietic Stem Cell Transplantation Market Industry is expanding thanks to the efforts of prominent organizations like the Korean Society of Haematology, who are actively raising awareness and improving treatment procedures. The demand for stem cell transplants is anticipated to increase as treatment choices, such as better methods and patient management practices, improve, reflecting hospitals' need to implement these cutting-edge medicines. **Advancements in Stem Cell Research** Advancements in stem cell research and technology are rapidly transforming treatment paradigms in the South Korea Hematopoietic Stem Cell Transplantation Market. South Korea has made significant strides in Research and Development (R&D) in this area, with a considerable increase in patents filed by institutions such as POSTECH and KAIST. The biotechnology sector in South Korea has seen investment growth, with over USD 1 billion allocated to stem cell research in recent years.As a result, enhanced methodologies for sourcing and processing stem cells are becoming available, making transplants more effective and safer.  Organizations like the Korea National Institute of Health are also playing a significant role in facilitating research and clinical trials, accelerating the transition from lab discoveries to clinical applications. These advancements foster greater confidence among healthcare providers in adopting hematopoietic stem cell transplants, significantly impacting the market's growth. **Government Support and Policy Initiatives** Government support and policy initiatives are critical drivers of the South Korea Hematopoietic Stem Cell Transplantation Market. The South Korean government has implemented numerous health policies focused on increasing healthcare accessibility and funding for advanced treatment options, including stem cell transplantation. In 2020, the Ministry of Health and Welfare introduced the Health Care Reform Plan, which allocated resources aimed at enhancing specialized medical centers for blood disorders.This commitment from the government ensures a stable environment for the development of the South Korea Hematopoietic Stem Cell Transplantation Market Industry, as it encourages clinical research and promotes public awareness programs. Additionally, financial aid for patients undergoing such treatments helps to remove economic barriers to accessing hemopoietic stem cell transplants, ensuring a steady demand trajectory. **Increased Awareness of Stem Cell Therapies** Increased awareness of stem cell therapies among both medical professionals and patients drives the South Korea Hematopoietic Stem Cell Transplantation Market. Educational campaigns initiated by patient advocacy groups and healthcare organizations have significantly improved understanding of the benefits and effectiveness of stem cell transplants. For instance, the Korea Society of Bone Marrow Transplantation regularly conducts seminars and workshops aimed at educating both healthcare providers and patients about treatment options, resulting in a reported 30% increase in patient inquiries regarding stem cell therapies.As patients become more informed, they are likelier to opt for these innovative treatments, which concurrently incentivizes healthcare providers to incorporate hemopoietic stem cell transplantation into their service offerings, further fostering market growth in South Korea. **South Korea Hematopoietic Stem Cell Transplantation Market Segment Insights** **Hematopoietic Stem Cell Transplantation Market Transplant Type Insights** The South Korea Hematopoietic Stem Cell Transplantation Market is prominently segmented by Transplant Type, which includes allogeneic and autologous transplants. The allogeneic segment involves transplanting stem cells from a genetically matched donor, providing a crucial option for patients with conditions such as leukemia or lymphomas, where the recipient’s immune system can benefit from the donor's healthy cells.  This segment is often considered significant due to its potential for graft-versus-leukemia effect, where donor cells attack the remaining cancer cells in the recipient, thus enhancing therapeutic outcomes.On the other hand, autologous transplants, where stem cells are harvested from the patient themselves, also hold a vital place in the market.  This method minimizes the risk of complications related to donor match issues and is often used in treating certain solid tumors and hematological disorders. The choice between allogeneic and autologous transplantation is influenced by various factors, such as the type of disease, the patient’s overall health, and the availability of a suitable donor. The trends observed in South Korea indicate a growing preference for these transplant types due to advancements in medical technology and increased awareness among healthcare professionals about effective treatment options. Enhanced techniques in stem cell harvesting and preservation have also contributed to the growth and efficiency of both transplant types within the industry. As the South Korea Hematopoietic Stem Cell Transplantation Market evolves, the dynamics of these transplants will significantly impact overall patient treatment outcomes, driving innovation and research in both fields. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Hematopoietic Stem Cell Transplantation Market Indication Insights** The South Korea Hematopoietic Stem Cell Transplantation Market is segmented based on Indication, a critical aspect that encompasses various hematological malignancies and disorders. Key indications include Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia, which have shown a rising trend in prevalence, driving demand for effective transplantation solutions. Hodgkin Lymphoma and Non-Hodgkin Lymphoma are significant players within this segment, benefiting from advancements in treatment methodologies that leverage stem cell transplants for better patient outcomes. Multiple Myeloma continues to be a focus, highlighting the growing importance of stem cell therapies in managing this chronic condition. Other Non-Malignant Disorders, while less prominent, present emerging opportunities as the understanding of stem cell applications expands. The increasing incidence rates of these diseases, combined with a robust healthcare infrastructure in South Korea, positions the Hematopoietic Stem Cell Transplantation Market favorably for growth. Additionally, collaborations between healthcare providers and research institutions may further bolster advancements in this field, enhancing treatment options and ultimately improving patient prognosis. **Hematopoietic Stem Cell Transplantation Market Application Insights** The South Korea Hematopoietic Stem Cell Transplantation Market focuses significantly on the Application segment, which includes Bone Marrow Transplant, Peripheral Blood Stem Cells Transplant, and Cord Blood Transplant. Bone Marrow Transplant has been a cornerstone of treatment for numerous hematologic disorders, reflecting its long-standing role in the healthcare landscape.  Peripheral Blood Stem Cells Transplant is gaining traction due to its advantages, such as quicker recovery times and less invasive nature, making it a preferred choice among clinicians.Cord Blood Transplant is emerging as an important alternative since it provides a rich source of stem cells, with increasing public awareness enhancing its use and acceptance. The growing incidence of blood-related disorders and the rising success rates of these procedures contribute to the market's growth trajectory.  Furthermore, heightened investment in technology and advancements in transplant techniques bolster the overall efficiency and safety of these operations, driving demand within the South Korea Hematopoietic Stem Cell Transplantation Market.The combination of evolving treatment protocols and increasing government support for research initiatives ensures a dynamic growth environment in this sector. **South Korea Hematopoietic Stem Cell Transplantation Market Key Players and Competitive Insights** The South Korea Hematopoietic Stem Cell Transplantation Market is a highly specialized and competitive landscape characterized by advanced medical technology and a considerable focus on research and development. This market is primarily driven by a growing incidence of hematologic diseases, such as leukemia and lymphomas, alongside an increase in the number of clinical trials and transplant procedures.  The unique features of the South Korean healthcare system, including government support and innovative healthcare policies, further bolster market opportunities. A robust demand for hematopoietic stem cell transplants has also encouraged various healthcare institutions to enhance their capabilities, which has intensified competition within this field. As healthcare providers strive to advance treatment methodologies, the market continues to evolve, introducing new players and technologies while existing institutions enhance their services.In this context, Yonsei University Health System stands out as a leader within the South Korea Hematopoietic Stem Cell Transplantation Market. The system is recognized for its commitment to providing comprehensive healthcare services, contributing significantly to the advancements in hematopoietic stem cell transplantation.  Possessing a strong reputation for clinical excellence, Yonsei University Health System employs cutting-edge clinical protocols and a multidisciplinary approach that improves patient outcomes. Its facilities are equipped with state-of-the-art medical technology that allows for the execution of complex transplant procedures. Additionally, their focus on continued medical education for healthcare professionals ensures that the latest techniques and therapies are implemented, maintaining their competitive edge in this sensitive market segment.Samsung Medical Center also plays a vital role in the South Korea Hematopoietic Stem Cell Transplantation Market, showcasing an extensive range of key services and innovative treatment options. Known for its comprehensive care and patient-centered approach, Samsung Medical Center supports both autologous and allogeneic stem cell transplants.  The presence of specialized transplant units, along with a strong emphasis on research, positions the center as a pivotal player in advancing transplantation techniques. Their collaboration with academic institutions, alongside strategic partnerships and potential mergers or acquisitions, has enhanced their capacity for research and development, facilitating groundbreaking therapies and improved clinical practices. With a commitment to adopting the latest technologies and treatment protocols, Samsung Medical Center continues to strengthen its market presence while maintaining high standards of quality and safety in patient care within the South Korean healthcare setting. **Key Companies in the South Korea Hematopoietic Stem Cell Transplantation Market Include** **South Korea Hematopoietic Stem Cell Transplantation Market Industry Developments** The South Korea Hematopoietic Stem Cell Transplantation Market has witnessed significant developments, particularly in the areas of research and collaboration among leading healthcare institutions. In recent months, Yonsei University Health System and Samsung Medical Center have announced joint initiatives to advance their research capabilities in hematopoietic stem cell therapies. Asan Medical Center has also been active in enhancing its transplant programs, focusing on improving patient outcomes through innovative approaches. Current affairs indicate a growing recognition of the importance of hematopoietic stem cell transplantation, with Korea University Anam Hospital and ChungAng University Hospital adopting new protocols to streamline patient care. Moreover, in September 2023, it was reported that Gachon University Gil Medical Center formed a strategic alliance with international organizations for the sharing of best practices and technology transfer in hematopoietic stem cell transplantation. In the past two to three years, there has been a notable increase in government funding aimed at expanding research efforts, strengthening Korea's position as a leader in this specialized field. Additionally, with the projected growth in market valuation, healthcare providers are strategically investing in advanced technologies and enhanced training programs to meet the rising demand for stem cell therapies effectively. **South Korea Hematopoietic Stem Cell Transplantation Market Segmentation Insights** ## Market Drivers ### Advancements in Stem Cell Research Ongoing advancements in stem cell research are significantly influencing the hematopoietic stem-cell-transplantation market. Research institutions in South Korea are focusing on innovative techniques to enhance the efficacy and safety of transplants. For instance, the development of gene editing technologies and improved donor matching algorithms may lead to better patient outcomes. The South Korean government has allocated over $50 million in funding for stem cell research initiatives in 2025, which is expected to accelerate the pace of discoveries. Such advancements not only improve treatment options but also attract investment into the hematopoietic stem-cell-transplantation market, fostering further growth. ### Expansion of Healthcare Infrastructure The expansion of healthcare infrastructure in South Korea is a vital driver for the hematopoietic stem-cell-transplantation market. With the government investing heavily in healthcare facilities and technologies, access to advanced medical services is improving. In 2025, the number of specialized transplant centers is expected to increase by 20%, providing more patients with access to hematopoietic stem-cell-transplantation. This growth in infrastructure not only enhances the capacity for performing transplants but also improves the overall quality of care. As a result, the hematopoietic stem-cell-transplantation market is poised for significant growth, driven by increased patient access and improved treatment outcomes. ### Rising Demand for Personalized Medicine The increasing demand for personalized medicine is reshaping the landscape of the hematopoietic stem-cell-transplantation market. Patients are increasingly seeking tailored treatment options that cater to their specific genetic profiles. This trend is particularly evident in South Korea, where healthcare providers are adopting precision medicine approaches. The market for personalized medicine is projected to grow at a CAGR of 12% over the next five years, indicating a robust interest in customized therapies. As healthcare systems evolve to accommodate this demand, the hematopoietic stem-cell-transplantation market is likely to benefit from enhanced treatment protocols and improved patient satisfaction. ### Collaboration Between Public and Private Sectors Collaboration between public and private sectors is emerging as a key driver for the hematopoietic stem-cell-transplantation market. Partnerships between government agencies, research institutions, and private companies are fostering innovation and improving treatment options. In South Korea, several initiatives have been launched to promote joint research projects and clinical trials, which are expected to enhance the development of new therapies. This collaborative approach is likely to lead to a more robust pipeline of treatments, thereby expanding the hematopoietic stem-cell-transplantation market. The synergy between public and private entities may also attract additional funding, further bolstering the industry's growth. ### Increasing Awareness of Stem Cell Transplantation The growing awareness regarding the benefits of hematopoietic stem-cell-transplantation is a crucial driver for the market in South Korea. Educational campaigns and initiatives by healthcare organizations have led to a better understanding of the procedure among patients and healthcare professionals. This heightened awareness is likely to increase the number of patients seeking treatment, thereby expanding the hematopoietic stem-cell-transplantation market. In 2025, it is estimated that approximately 15,000 stem cell transplants will be performed in South Korea, reflecting a 10% increase from previous years. This trend indicates a shift in public perception, which is essential for the growth of the industry. ## Future Outlook The [Hematopoietic Stem Cell Transplantation Market](https://www.marketresearchfuture.com/reports/hematopoietic-stem-cell-transplantation-market-21548) is projected to grow at a 12.22% CAGR from 2025 to 2035, driven by advancements in technology, increasing patient demand, and enhanced treatment protocols. **New opportunities:** - Development of personalized stem cell therapies for niche markets. - Expansion of telehealth services for pre- and post-transplant care. - Investment in automated cell processing technologies to improve efficiency. By 2035, the market is expected to achieve substantial growth, driven by innovation and increased accessibility. ## Segment Insights ### By Transplant Type: Allogeneic (Largest) vs. Autologous (Fastest-Growing) In the South Korea hematopoietic stem-cell-transplantation market, the allogeneic transplant type holds the largest share due to its ability to treat a wider range of hematologic diseases. Allogeneic transplants are performed using stem cells from a donor, which provides a genetic match that significantly increases the chances of a successful outcome. Conversely, autologous transplants, where patients use their own stem cells, are gaining traction as the fastest-growing segment. This growth can be attributed to the increasing awareness and advancements in medical technology, paving the way for more successful outcomes. The growth trends indicate a shift in preference towards autologous transplants, primarily driven by the rise in cancer cases and improvements in pre-transplant conditioning regimens. Furthermore, the enhanced safety profile and lower risk of complications associated with autologous procedures make them more appealing to patients and healthcare providers. The continuing evolution in stem cell therapies and supportive care is likely to boost the adoption of both transplant types, but autologous remains closely watched as it captures a growing segment of the market. Transplant Type: Allogeneic (Dominant) vs. Autologous (Emerging) Allogeneic transplants dominate the South Korea hematopoietic stem-cell-transplantation market due to their effectiveness in treating various blood disorders and cancers. These procedures involve using donor stem cells, often resulting in better long-term patient outcomes when matched correctly. On the other hand, autologous transplants are emerging as a preferred choice for many patients, particularly in addressing multiple myeloma and lymphoma. The ability of patients to use their own stem cells not only reduces the risk of graft-versus-host disease but also speeds up recovery times. As healthcare infrastructure continues to improve, both transplant types are likely to expand, with autologous transplants increasingly recognized for their role in patient-centric care. ### By Indication: Acute Myeloid Leukemia (Largest) vs. Acute Lymphoblastic Leukemia (Fastest-Growing) In the South Korea hematopoietic stem-cell-transplantation market, Acute Myeloid Leukemia (AML) holds the largest share due to its prevalent diagnosis and the active treatment of patients through stem cell transplants. Meanwhile, Acute Lymphoblastic Leukemia (ALL) is emerging as a significantly vital segment, characterized by rapid treatment advancements and increased patient awareness that is driving its growth trajectory. The growth trends within this market segment are fueled by a combination of factors including technological advancements, heightened healthcare investments, and an increasing incidence of blood-related disorders in the region. Both AML and ALL are drawing attention, with the latter positioned for rapid expansion as research progresses and treatment methodologies improve, indicating a dynamic shift in treatment protocols over the coming years. Acute Myeloid Leukemia (Dominant) vs. Acute Lymphoblastic Leukemia (Emerging) Acute Myeloid Leukemia (AML) is regarded as the dominant indication in the South Korea hematopoietic stem-cell-transplantation market, largely due to its high incidence rates and established treatment protocols. Patients diagnosed with AML often require urgent intervention, leading to a robust demand for stem cell transplant procedures. Conversely, Acute Lymphoblastic Leukemia (ALL) is marked as an emerging indication, showcasing swift growth potential. This segment benefits from evolving therapies and improved outcomes, positioning it favorably in the market. Growth in ALL is further supported by recent research breakthroughs and clinical trials that enhance treatment efficacy, contributing to its appeal for healthcare practitioners and patients alike. ### By Application: Bone Marrow Transplant (Largest) vs. Peripheral Blood Stem Cells Transplant (Fastest-Growing) In the South Korea hematopoietic stem-cell-transplantation market, the distribution of market share among the application segments shows a clear preference for Bone Marrow Transplant, which holds the largest share due to its long-established history and effectiveness. In contrast, Peripheral Blood Stem Cells Transplant is gaining traction, reflecting a growing acceptance and understanding of its benefits in various treatment protocols. Cord Blood Transplant, while present, occupies a smaller share of the market, primarily due to awareness and availability issues. Growth trends in this segment are driven by technological advancements and improved patient outcomes associated with Peripheral Blood Stem Cells Transplant, making it the fastest-growing segment. The increasing prevalence of hematological diseases and the rising demand for effective treatment options are also influencing this growth. Additionally, growing awareness around the benefits of Cord Blood Transplant is gradually fostering a shift in market dynamics, promoting more research and clinical applications. Application: Bone Marrow Transplant (Dominant) vs. Peripheral Blood Stem Cells Transplant (Emerging) Bone Marrow Transplant remains the dominant application in the South Korea hematopoietic stem-cell-transplantation market, primarily due to its proven efficacy in treating a variety of blood disorders and its established protocols within healthcare systems. It is often the first choice among clinicians for patients requiring stem-cell therapies. Conversely, Peripheral Blood Stem Cells Transplant is emerging as a credible alternative, gaining popularity for its less invasive nature and quicker recovery times compared to bone marrow procedures. As treatment methodologies evolve, the shift towards this emerging application is expected to lead to a more balanced market landscape, with both methodologies contributing significantly to patient care. ## Competitive Benchmarking The hematopoietic stem-cell-transplantation market in South Korea is characterized by a dynamic competitive landscape, driven by advancements in treatment methodologies and increasing patient demand. Key players such as Novartis (CH), Bristol-Myers Squibb (US), and Takeda (JP) are actively shaping the market through strategic initiatives focused on innovation and regional expansion. Novartis (CH) emphasizes its commitment to research and development, particularly in gene therapies, which positions it favorably in a market that increasingly values cutting-edge treatment options. Meanwhile, Bristol-Myers Squibb (US) has been enhancing its portfolio through strategic partnerships aimed at improving patient access to therapies, thereby reinforcing its market presence. Takeda (JP) is also notable for its focus on localized manufacturing, which not only optimizes supply chains but also aligns with the growing demand for personalized medicine in the region.The competitive structure of the market appears moderately fragmented, with several key players vying for market share. This fragmentation is indicative of a landscape where localized strategies, such as supply chain optimization and tailored treatment options, are becoming increasingly vital. The collective influence of these companies suggests a trend towards collaboration and innovation, as they seek to differentiate themselves in a crowded marketplace. In October Novartis (CH) announced a groundbreaking partnership with a leading South Korean research institution to develop next-generation CAR-T cell therapies. This collaboration is expected to enhance Novartis's capabilities in delivering personalized treatments, thereby solidifying its competitive edge in the region. The strategic importance of this partnership lies in its potential to accelerate the development of innovative therapies that cater to the unique needs of South Korean patients, ultimately driving market growth. In September Bristol-Myers Squibb (US) launched a new initiative aimed at increasing access to hematopoietic stem-cell-transplantation therapies for underserved populations in South Korea. This initiative, which includes educational programs for healthcare providers and patients, underscores the company's commitment to addressing healthcare disparities. By focusing on access, Bristol-Myers Squibb (US) not only enhances its corporate social responsibility profile but also positions itself as a leader in patient-centric care. In August Takeda (JP) expanded its manufacturing capabilities in South Korea by investing in a new facility dedicated to the production of stem-cell therapies. This strategic move is likely to enhance Takeda's operational efficiency and responsiveness to local market demands. The establishment of this facility reflects a broader trend towards localized production, which is becoming increasingly important in ensuring supply chain reliability and meeting the specific needs of the South Korean market. As of November the competitive trends in the hematopoietic stem-cell-transplantation market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in treatment protocols. Strategic alliances among key players are shaping the landscape, fostering innovation and enhancing patient outcomes. The shift from price-based competition to a focus on technological advancement and supply chain reliability is evident, suggesting that future competitive differentiation will hinge on the ability to innovate and adapt to evolving market demands. ## Recent News & Developments The South Korea Hematopoietic Stem Cell Transplantation Market has witnessed significant developments, particularly in the areas of research and collaboration among leading healthcare institutions. In recent months, Yonsei University Health System and Samsung Medical Center have announced joint initiatives to advance their research capabilities in hematopoietic stem cell therapies. Asan Medical Center has also been active in enhancing its transplant programs, focusing on improving patient outcomes through innovative approaches. Current affairs indicate a growing recognition of the importance of hematopoietic stem cell transplantation, with Korea University Anam Hospital and ChungAng University Hospital adopting new protocols to streamline patient care. Moreover, in September 2023, it was reported that Gachon University Gil Medical Center formed a strategic alliance with international organizations for the sharing of best practices and technology transfer in hematopoietic stem cell transplantation. In the past two to three years, there has been a notable increase in government funding aimed at expanding research efforts, strengthening Korea's position as a leader in this specialized field. Additionally, with the projected growth in market valuation, healthcare providers are strategically investing in advanced technologies and enhanced training programs to meet the rising demand for stem cell therapies effectively. ## Report Scope | MARKET SIZE 2024 | 98.09(USD Million) | | --- | --- | | MARKET SIZE 2025 | 110.07(USD Million) | | MARKET SIZE 2035 | 348.76(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 12.22% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Novartis (CH), Bristol-Myers Squibb (US), Amgen (US), Gilead Sciences (US), Celgene (US), Takeda (JP), Roche (CH), Merck (DE), AstraZeneca (GB) | | Segments Covered | Transplant Type, Indication, Application | | Key Market Opportunities | Advancements in gene editing technologies enhance treatment efficacy in the hematopoietic stem-cell-transplantation market. | | Key Market Dynamics | Rising demand for hematopoietic stem-cell-transplantation driven by advancements in treatment protocols and regulatory support. | | Countries Covered | South Korea | ## Frequently Asked Questions **Q: What was the market valuation of the South Korea hematopoietic stem-cell-transplantation market in 2024?** A: The market valuation was $98.09 Million in 2024. **Q: What is the projected market valuation for the South Korea hematopoietic stem-cell-transplantation market by 2035?** A: The projected valuation for 2035 is $348.76 Million. **Q: What is the expected CAGR for the South Korea hematopoietic stem-cell-transplantation market during the forecast period 2025 - 2035?** A: The expected CAGR during this period is 12.22%. **Q: Which companies are considered key players in the South Korea hematopoietic stem-cell-transplantation market?** A: Key players include Novartis, Bristol-Myers Squibb, Amgen, Gilead Sciences, Celgene, Takeda, Roche, Merck, and AstraZeneca. **Q: What were the valuations for allogeneic and autologous transplants in 2024?** A: Both allogeneic and autologous transplants were valued at $49.05 Million and $49.04 Million, respectively. **Q: How do the valuations for acute myeloid leukemia and acute lymphoblastic leukemia compare in 2024?** A: Acute myeloid leukemia was valued at $20.0 Million, while acute lymphoblastic leukemia was valued at $15.0 Million. **Q: What was the valuation for peripheral blood stem cell transplants in 2024?** A: The valuation for peripheral blood stem cell transplants was $40.0 Million in 2024. **Q: What is the projected growth for non-Hodgkin lymphoma treatment in the South Korea hematopoietic stem-cell-transplantation market?** A: The projected valuation for non-Hodgkin lymphoma is expected to reach $90.0 Million by 2035. **Q: What were the valuations for bone marrow transplants and cord blood transplants in 2024?** A: Bone marrow transplants were valued at $30.0 Million, while cord blood transplants were valued at $28.09 Million. **Q: What is the expected trend for the South Korea hematopoietic stem-cell-transplantation market in the coming years?** A: The market is likely to experience substantial growth, reaching $348.76 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-hematopoietic-stem-cell-transplantation-market-50034*